<DOC>
	<DOCNO>NCT03029455</DOCNO>
	<brief_summary>Evaluate safety tolerability VX-659 healthy subject</brief_summary>
	<brief_title>A Study Evaluate Safety Pharmacokinetics VX-659 Healthy Subjects Adults With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Healthy Volunteers : PARTS A , B , C Males Females nonchildbearing potential . Between age 18 60 year inclusive Healthy , define per protocol . Body mass index ( BMI ) 18.0 32.0 kg/m2 inclusive Body weight &gt; 50 kg CF Patients : PART D Body weight ≥35 kg . Males Females nonchildbearing potential . Sweat chloride value ≥ 60 mmol/L screening . Heterozygous F508del minimal function CFTR mutation Forced expiratory volume 1 second ( FEV1 ) ≥40 % ≤90 % predicted screening Healthy Volunteers : PARTS A , B , C History illness clinical condition opinion investigator might confound result study pose additional risk subject . Any condition possibly affect drug absorption . History febrile illness within 14 day first study drug dose . Glucose6phosphate dehydrogenase ( G6PD ) deficiency assess Screening . CF Patients : PART D History comorbidity , opinion investigator , might confound result study pose additional risk subject . History cirrhosis portal hypertension . Risk factor Torsade de Pointes . G6PD deficiency assess Screening . Abnormal Laboratory Values . Lung infection organisms associate rapid decline pulmonary status History solid organ hematological transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>